Extending the chimeric receptor-based t-cell targeting strategy to solid tumors

OncoImmunology

Volumn 2, Issue 10, 2013, Pages

  Rossig, Claudia ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

CD19; Chimeric receptor; Gangliosides; Target antigen; Tumor microenvironment

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; GANGLIOSIDE GD2; GANGLIOSIDE GD3; LYMPHOCYTE ANTIGEN RECEPTOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; NONHUMAN; SOLID TUMOR; T LYMPHOCYTE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84890291467     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.26091     Document Type: Article

References (10)

1. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95ra73; PMID:21832238; http://dx.doi.org/10.1126/scitranslmed.3002842
2. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy- refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5:In press; PMID:23515080; http://dx.doi.org/10.1126/scitranslmed.3005930
3. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368:1509-18; PMID:23527958; http://dx.doi. org/10.1056/NEJMoa1215134
4. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011; 118:6050-6; PMID:21984804; http://dx.doi.org/10.1182/blood-2011-05-354449
5. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008; 14:1264-70; PMID:18978797; http://dx.doi.org/10.1038/nm.1882
6. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, et al. A phase I study on adoptive immunotherapy using genemodified T cells for ovarian cancer. Clin Cancer Res 2006; 12:6106-15; PMID:17062687; http://dx.doi.org/10.1158/1078-0432.CCR-06-1183
7. Rehe K, Wilson K, Bomken S, Williamson D, Irving J, den Boer ML, Stanulla M, Schrappe M, Hall AG, Heidenreich O, et al. Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations. EMBO Mol Med 2013; 5:38-51; PMID:23229821; http://dx.doi.org/10.1002/emmm.201201703
8. Kailayangiri S, Altvater B, Meltzer J, Pscherer S, Luecke A, Dierkes C, Titze U, Leuchte K, Landmeier S, Hotfilder M, et al. The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer 2012; 106:1123-33; PMID:22374462; http://dx.doi.org/10.1038/bjc.2012.57
9. Liebsch L, Kailayangiri S, Beck L, Altvater B, Koch R, Dierkes C, Hotfilder M, Nagelmann N, Faber C, Kooijman H, et al. Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging. Br J Cancer 2013; 109:658-66; PMID:23839490; http://dx.doi.org/10.1038/bjc.2013.356
10. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690